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We report the case of a lung transplant recipient in whom the diagnostic of visceral leishmaniasis (VL) 26 
was made by detection of parasites in a peripheral blood (PB) smear when the parasite load already 27 
reached 8.9 x 103 parasites per millilitres. We demonstrated that the VL diagnosis could have been done 28 
months before the development of symptoms by the use of Leishmania-specific real-time PCR, 29 
suggesting the usefulness a role of pre-emptive PCR-based diagnosis in transplant recipients at risk for 30 
VL.  31 
  32 
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Leishmaniasis is a severe vector borne-disease caused by a group of protozoan parasites of the genus 33 
Leishmania, transmitted to humans by the bite of infected female phlebotomine sandflies (1). There are 3 34 
main forms of the disease: visceral leishmaniasis (VL), cutaneous leishmaniasis and mucocutaneous 35 
leishmaniasis. VL, the more severe form, is fatal if left untreated. An estimated 1.3 million new VL cases 36 
and 20,000 to 30,000 deaths occur annually with an increasing number of cases among 37 
immunocompromised patients (1-4). In solid-organ transplant (SOT) recipients, VL diagnosis is rare and 38 
often delayed; indeed 25% of VL final diagnostics may occur more than 1 month after symptoms onset 39 
(5). Polymerase chain reaction (PCR) for Leishmania has improved the initial diagnosis of VL both in 40 
immunocompromised and in immunocompetent patients, with a high sensitivity and specificity (70% - 41 
100% and 95% - 100% respectively) (6). Additionally, highly sensitive specific real-time PCR allows the 42 
assessment of the response to treatment by monitoring the parasitic load in PB (7). However, the use of 43 
PCR for the assessment of Leishmania load in PB in asymptomatic immunocompromised patients at risk 44 
for reactivation has been insufficiently assessed. We report a case of a lung transplant recipient in whom 45 
early diagnosis of VL could have been done months before the development of symptoms by the use of 46 
Leishmania PCR, thus supporting the usefulness of this method for VL pre-emptive diagnosis.  47 
 48 
Case report 49 
A 61-year-old Swiss man underwent bilateral lung transplantation for idiopathic pulmonary fibrosis in 50 
June 2013. Additional pre-transplantation medical history included a past hepatitis B virus infection. 51 
After transplantation, the patient received the standard immunosuppressive regimen with oral prednisone, 52 
mycophenolate mofetil (MMF), and tacrolimus. In July 2014, he developed a persistent pancytopenia 53 
without any associated symptoms (unremarkable clinical examination, no hepatosplenomegaly and no 54 
lymphadenopathy). The initial tests excluded iron and vitamin deficiency. No splenomegaly was seen on 55 
the abdominal CT scan performed in January 2015. The PB smear showed no platelet aggregations, no 56 
evidence of microangiopathy and no schizocytes. A PCR assay performed in the PB was negative for 57 
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cytomegalovirus, Epstein-Barr virus, parvovirus B19, human-herpes virus 6 and hepatitis B virus. The 58 
serologic assays for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) were negative.  In 59 
April 2015, a bone marrow biopsy showed a normocellular bone marrow with hyperplasia of the erythroid 60 
lineage, a left shift in the granulocyte lineage, a normal percentage of blasts, a discrete lymphocytosis 61 
with a predominance of probably reactive T cells and no fibrosis. The cytological examination excluded a 62 
post-transplant lymphoproliferative disorder (PTLD) or a myelodysplastic syndrome. The microbiological 63 
analyses performed on the bone marrow remained all negative. Based on all these analyses a drug-64 
induced pancytopenia was suspected and we decided to discontinue trimethoprim/sulfamethoxazole (used 65 
for Pneumocystis pneumonia prophylaxis) on September 2014 and later MMF on April 2015, and 66 
eventually replace tacrolimus by cyclosporine. Despite that, the pancytopenia worsened and a treatment 67 
with G-CSF stimulator was administered.  68 
 On June 2015 the examination of a PB smear showed an important number of macrophages and 69 
neutrophils containing intracellular organisms strongly evocating the amastigotes form of Leishmania. 70 
We also noticed a polyclonal hypergammaglobulinemia that was not present earlier. The definite 71 
diagnosis was made by real-time PCR detection of Leishmania DNA - 8.9 x 107 kinetoplastic DNA 72 
copies/ml - in PB, which corresponded to 8.9 x 103 parasites per ml, as the PCR targets the kinetoplastic 73 
DNA present in about 10,000 copies per parasite (Figure 1) (8). By PCR-restriction fragment length 74 
polymorphism (RFLP) based on the rRNA miniexon sequence (9) we could not distinguish between L. 75 
infantum and L. donovani. Treatment of liposomal amphotericin B was initiated at 3mg/kg per day 76 
intravenously for 5 days followed by another 6 doses of 4mg/kg once a week. Clinical and biological 77 
evolution was favourable with rapid improvement in total blood count and absence of parasite detection 78 
in PB approximately 3 weeks after amphotericin B introduction (Figure 1). A monthly follow-up by PCR 79 
did not detect any parasite DNA at 6 months after discontinuation of amphotericin B. MMF and 80 
trimethoprim/sulfamethoxazole were reintroduced on July 2015 and September 2015, respectively and no 81 
relapse of pancytopenia was observed. 82 
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 We intended to determine the time of the initial infection based on travel history (the patient reported 83 
a trip to Greece July 2014, 13 months after transplant) and PCR on previous samples. The retrospective 84 
examination of the myelogram obtained 5 weeks before the diagnosis of VL revealed the presence of 85 
some parasites and the Leishmania PCR was positive with 7.2 x 105 kinetoplastic DNA copies/ml (Figure 86 
1). As DNA extracted from the patient’s blood samples collected after transplantation were available 87 
since the patient was routinely followed-up at the transplantation clinic of our hospital in a regular basis, 88 
we decided to retrospectively test them using the Leishmania specific PCR. Interestingly, the Leishmania 89 
PCR was already positive in samples collected more than 18 months before the first diagnosis, at a time 90 
were the patient was fully asymptomatic (Figure 1). However, our first appreciation that the infection was 91 
contracted during his trip in Greece was ruled out. We thus hypothesize that the infection occurred some 92 
years before transplantation, a period during which the patient reported several travels in endemic areas: 93 
Morocco in 2000, 3-4 trips to the south of France the last in 2007, Turkey in 2010, Andalusia in 2011, 94 
and Crete in 2012. The serology for Leishmania performed retrospectively on sera collected at the time of 95 




The diagnosis of VL in SOT recipients is challenging even in endemic areas; Clemente et al. reported that 100 
only one third of the patients presented the classic triad (fever, visceromegaly and pancytopenia) at time 101 
of diagnosis (5). VL is a rare opportunistic infection SOTs but should be included in the differential 102 
diagnosis of fever of unknown origin and/or pancytopenia. Two cases of VL in SOT recipients living in 103 
Switzerland have already been reported; a kidney transplant recipient after holidays in Spain and Tunisia 104 
(10) and a liver transplant recipient following a trip to Turkey (11). So far, only 7 cases have been 105 
reported in lung transplant recipients (3, 5).  Noteworthy, because patients may be asymptomatic for long 106 
periods of time, a travel history in an endemic area may be easily overlooked.  Our analysis demonstrates 107 
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that VL diagnostic could have been made up to 18 months earlier in the present case through the detection 108 
of Leishmania DNA using a highly sensitive Leishmania specific real-time PCR (5, 8). In particular PCR 109 
targeting kinetoplastic DNA which is present in up to 10’000 copies per parasite would allow a very early 110 
detection of infection in PB, a precise monitoring of the parasite burden and can be also used for the 111 
monitoring of the response to therapy including the detection of episodes of relapse. We thus recommend 112 
including PCR as a rapid and non-invasive screening method for VL diagnosis in at risk’s SOT recipients. 113 
 114 
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Figure 1: Kinetic of Leishmania DNA detection in peripheral blood and bone marrow using a 156 
specific real-time PCR prior and after the initial diagnostic of visceral leishmaniasis.  157 
The main graphic represents Leishmania detection using a specific real-time PCR targeting a sequence of 158 
the kinetoplastic DNA. On June 22th 2015, a thin blood smear stained with Giemsa revealed several 159 
leucocytes infected with Leishmania sp. amastigotes. The diagnostic of leishmaniasis was made by real-160 
time PCR detection of Leishmania DNA on this sample, 8.9 x 107 kinetoplastic DNA copies/ml, which 161 
corresponded to 8.9 x 103 parasites per ml as the PCR targets the kinetoplastic DNA present in up to 162 
10,000 copies per parasite. The PCR performed retrospectively on a bone marrow puncture sampled in 163 
May 2015 was positive with 7.2 x 105 kinetoplastic DNA copies/ml. DNA from peripheral blood samples 164 
collected at the transplantation clinic of our hospital were retrospectively tested in our molecular 165 
diagnostic laboratory and revealed that the first positive PCR occurred in sample collected the 18th 166 
December 2013 (890 kinetoplastic DNA copies/ml), long before the beginning of the pancytopenia, 167 
which started in July 2014.  168 
 169 
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